Cocaine Use Disorder Clinical Trial
Official title:
Occupational Therapy-Based Cognitive Rehabilitation of Cocaine Abusers: A Pilot Study
Verified date | June 2019 |
Source | University of California, San Francisco |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study integrates a model of occupational-therapy based cognitive rehabilitation as part of a comprehensive treatment plan for cocaine abusers. We hypothesize that cognitive impairment and quality of life would improve and that cocaine use would decrease in those participants receiving occupational-therapy based cognitive rehabilitation.
Status | Completed |
Enrollment | 50 |
Est. completion date | March 31, 2019 |
Est. primary completion date | March 31, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: 1. Age 18-65 2. Primary cocaine use disorder (based on DSM-5 criteria) and in at least 3 months of remission 3. At least mild cognitive impairment, defined as = or > 1.5 standard deviations impairment on any 2 performance-based neurocognitive measures 4. Needing to change quality of life, defined as self-identifying at least 2 life areas as needing to change on the Drug User Quality of Life Scale 5. A Veteran at the San Francisco Veterans Affairs Medical Center 6. Currently receiving weekly drug counseling (individual or group; at least 1 hour/week) through an outpatient substance use disorder treatment program Exclusion Criteria: 1. Inability to speak, read, write, and understand English 2. Inadequate hearing or vision 3. Concurrent substance use disorder (except tobacco or caffeine) not in at least 3 months of remission 4. A psychiatric disorder that will interfere with study participation or will make participation hazardous (e.g., psychosis, suicidal or homicidal ideations, severe anxiety) 5. A depressive disorder classified as severe, defined as a Beck Depression Inventory-II score >29 6. Current diagnosis of a bipolar disorder needing acute inpatient psychiatric hospitalization 7. Currently symptomatic from attention-deficit/hyperactivity disorder (DSM-5 criteria) 8. Any learning disorder, any type of dementia, any type of delirium, or an amnestic disorder due to any general medical condition 9. Wechsler Test of Adult Reading standard score <70 10. Mini-Mental State Examination score <24 11. Current use of scheduled (i.e., prescribed) regular (i.e., daily) psychotropics or other medicines with a high likelihood of sedation & cognitive impairment (e.g., benzodiazepines, clozapine, anticholinergics) 12. Currently prescribed stimulants (e.g., methylphenidate) or cognitive enhancers (e.g., donepezil, memantine) 13. Active medical illnesses - uncontrolled diabetes, uncontrolled hypertension, uncontrolled thyroid dysfunction, or uncontrolled B12/folate deficiency; central nervous system illness with potential cognitive aspects (Parkinson's, or Huntington's dementia); Cirrhosis with complications (e.g., ascites, encephalopathy, jaundice, gastrointestinal bleeding); Needing acute medical hospitalization from HIV sequelae, such as HIV-related opportunistic infection 14. Any history of any type of stroke or brain hemorrhage 15. Any history of traumatic brain injury, intracranial pathology (e.g., tumor), or brain surgery 16. Currently on probation or parole 17. Concurrent participation in another study that medically/administratively interferes with this study |
Country | Name | City | State |
---|---|---|---|
United States | University of California, San Francisco & San Francisco Veterans Affairs Medical Center | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
University of California, San Francisco | San Francisco Veterans Affairs Medical Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in cognitive impairment | Global Deficit Score, range 0 (no impairment) to 5 (severe impairment) | baseline through 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03538548 -
Treatment Outcome in CBT for Cocaine Use
|
N/A | |
Recruiting |
NCT04994821 -
tDCS to Reduce Craving in Cocaine Addiction- Phase 2 Study
|
Phase 2 | |
Not yet recruiting |
NCT06050304 -
CRACK-TARGET 1: ÉTUDE DESCRIPTIVE DE LA SENSIBILISATION COMPORTEMENTALE OBSERVÉE et ATTENTES
|
||
Completed |
NCT02239913 -
Topiramate-Phentermine Combinations for Cocaine Dependence
|
Phase 1 | |
Completed |
NCT02233647 -
Phendimetrazine and Cocaine
|
Early Phase 1 | |
Not yet recruiting |
NCT05974202 -
rTMS and Cognitive-behavioral Therapy for Cocaine Use Disorder
|
Phase 2 | |
Recruiting |
NCT04927143 -
Encouraging Abstinence Behavior in a Drug Epidemic
|
Phase 2 | |
Completed |
NCT03224546 -
Cocaine Use Reduction and Health
|
N/A | |
Recruiting |
NCT03656653 -
Imagery-based Coping for Cocaine Use Disorder
|
N/A | |
Completed |
NCT03348384 -
[11C]NOP-1A and Cocaine Use Disorders
|
Early Phase 1 | |
Recruiting |
NCT05019430 -
Cocaine and Zolmitriptan
|
Early Phase 1 | |
Recruiting |
NCT03344419 -
Glutamatergic Modulation to Facilitate the Behavioral Treatment of Cocaine Use Disorders
|
Phase 3 | |
Recruiting |
NCT05507814 -
Temporal Window and Episodic Future Thinking in CUD
|
N/A | |
Active, not recruiting |
NCT03799341 -
Neurocognitive Factors in Substance Use Treatment Response: The Ways of Rewarding Abstinence Project
|
N/A | |
Completed |
NCT02785406 -
Role of the Orexin Receptor System in Stress, Sleep and Cocaine Use
|
Phase 2 | |
Completed |
NCT02798627 -
Trial Of NS2359 For The Treatment of Cocaine Dependence
|
Phase 2 | |
Completed |
NCT02444208 -
A Feasibility Trial for Inhibitory-Control Training to Reduce Cocaine Use
|
N/A | |
Recruiting |
NCT05902819 -
Reconsolidation Blockade of Intrusive Trauma- and Cocaine-related Memories
|
N/A | |
Recruiting |
NCT05521854 -
Contingency Management for Drug Use: Does Age Matter?
|
N/A | |
Recruiting |
NCT05833529 -
Innovative Cognitive and Behavioral Psychotherapy for Cocaine Use Disorder
|
N/A |